Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax monotherapy in relapsed or refractory mantle cell lymphoma
MOH_2023-05-30_012688Phase 2Recruiting
- Sponsor
- BeiGene
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonrotoclax in mantle cell lymphoma (MCL), sponsored by BeiGene. Primary endpoints: Safety and tolerability and Recommended Phase 2 dose. Started Mar 2023; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on MOH_2023-05-30_012688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-30_012688.